Idoxifene vs Tamoxifen in Preventing Breast Cancer in Rats
Author Information
Author(s): P Pace, M Jarman, D Phillips, A Hewer, J Bliss, RC Coombes
Primary Institution: Cancer Research Campaign Laboratories, Department of Medical Oncology, Charing Cross & Westminster Medical School
Hypothesis
Idoxifene is as effective as tamoxifen in preventing mammary carcinogenesis while causing fewer hepatic DNA adducts.
Conclusion
Idoxifene is as effective as tamoxifen in preventing mammary tumors in rats but results in significantly lower levels of DNA adducts in the liver.
Supporting Evidence
- Idoxifene and tamoxifen both prevented tumor growth in treated rats.
- Only 10% of vehicle-treated animals were alive and tumor-free after 24 weeks.
- Idoxifene-treated animals had significantly lower levels of hepatic DNA adducts compared to tamoxifen-treated animals.
Takeaway
This study shows that idoxifene can help stop breast cancer in rats just like tamoxifen, but it doesn't hurt the liver as much.
Methodology
The study compared the effects of idoxifene and tamoxifen on mammary carcinogenesis in rats treated with MNU, measuring tumor development and hepatic DNA adduct formation.
Limitations
The study was conducted in rats, and results may not directly translate to humans.
Participant Demographics
In-bred virgin female Ludwig/Wistar/Olac rats, aged 45-55 days.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website